Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Hold
0
-$4 4727
2023
Q2
Hold
0
4487
2023
Q1
Hold
0
5027
2022
Q4
Hold
0
5228
2022
Q3
Hold
0
5186
2022
Q2
Hold
0
5302
2022
Q1
Hold
0
5716
2021
Q4
Sell
-31
Closed -$18K 4807
2021
Q3
$23K Buy
31
+22
+244% +$18.4K ﹤0.01% 4350
2021
Q2
$10K Buy
9
+2
+29% +$2.39K ﹤0.01% 4653
2021
Q1
$10K Buy
+7
New +$10.2K ﹤0.01% 4437
2020
Q3
Sell
-24
Closed -$16K 5637
2020
Q2
$16K Sell
24
-3
-11% -$1.35K ﹤0.01% 5250
2020
Q1
$9K Sell
27
-2
-7% -$789 ﹤0.01% 5854
2019
Q4
$23K Buy
29
+15
+107% +$18K ﹤0.01% 5951
2019
Q3
$21K Sell
14
-3
-18% -$4.81K ﹤0.01% 6201
2019
Q2
$37K Buy
+17
New +$34.5K ﹤0.01% 6226
2019
Q1
Hold
0
7373

Other funds holding YCBD

Barclays's YCBD Position: Q3 2023 in Review

Barclays held its cbdMD (YCBD) position steady in Q3 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4727.

Barclays first reported a position in YCBD in Q2 2019 and has held it in 8 quarters since. The position peaked at $37K in Q2 2019. 20 funds tracked by Wall St. Rank hold YCBD as of Q3 2023.

  • Barclays held 0 shares of cbdMD worth $0 as of Q3 2023.
  • Barclays left its cbdMD share count unchanged in Q3 2023.
  • cbdMD made up ﹤0.01% of Barclays's portfolio in Q3 2023, its #4727 holding.
  • Barclays first reported a position in cbdMD in Q2 2019 and has held it in 8 quarters since.
  • Barclays's cbdMD position peaked at $37K in Q2 2019.
  • 20 funds tracked by Wall St. Rank held cbdMD as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.